Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Resolute™ Integrity Zotarolimus-Eluting Stent in Coronary Artery Disease: A Review

The Resolute™ Integrity Zotarolimus-Eluting Stent in Coronary Artery Disease: A Review The introduction of first-generation drug-eluting stents (DES) was a major advance in the percutaneous treatment of coronary artery disease, with DES significantly reducing the incidence of restenosis and major adverse coronary events compared with bare metal stents. Next-generation DES now utilizes lower profiles, thinner struts, and other technological advances to help extend their safety and efficacy. Importantly, studies of next-generation devices have now gone beyond controlled clinical trials with selected populations to registries and studies with all-comer populations, where more diverse and complex sets of patients and lesions have been managed. Thus, a large body of evidence and comparative data about the safety and efficacy of these devices has accumulated. The Resolute™ zotarolimus-eluting stent (R-ZES; Medtronic Inc., Santa Rosa, CA, USA) is a next-generation DES that uses a novel biocompatible polymer on a cobalt alloy stent platform to extend the duration of drug elution and improve the stent’s efficacy. The Integrity™ platform (Medtronic, Inc., Santa Rosa, CA, USA) used in the most recent iteration of the R-ZES stent further enhances the flexibility and deliverability of the stent in complex lesions by incorporation of a continuous sinusoidal design. In the following review, the clinical data is critically examined for the R-ZES and discuss its performance using comparative data currently available for next-generation DES. It is concluded that R-ZES use in complex patients and lesions is associated with durable efficacy and safety and represents another generational improvement in DES technology, which undoubtedly will enhance patient outcomes postpercutaneous coronary interventional. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cardiology and Therapy Springer Journals

The Resolute™ Integrity Zotarolimus-Eluting Stent in Coronary Artery Disease: A Review

Banerjee, Subhash
Cardiology and Therapy , Volume 2 (1) – Jan 4, 2013
Download PDF
9 pages

Loading next page...
 
/lp/springer-journals/the-resolute-integrity-zotarolimus-eluting-stent-in-coronary-artery-ry100n41IB
Publisher
Springer Journals
Copyright
Copyright © 2012 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine; Cardiology
ISSN
2193-8261
eISSN
2193-6544
DOI
10.1007/s40119-012-0010-z
pmid
25135286
Publisher site
See Article on Publisher Site

Abstract

The introduction of first-generation drug-eluting stents (DES) was a major advance in the percutaneous treatment of coronary artery disease, with DES significantly reducing the incidence of restenosis and major adverse coronary events compared with bare metal stents. Next-generation DES now utilizes lower profiles, thinner struts, and other technological advances to help extend their safety and efficacy. Importantly, studies of next-generation devices have now gone beyond controlled clinical trials with selected populations to registries and studies with all-comer populations, where more diverse and complex sets of patients and lesions have been managed. Thus, a large body of evidence and comparative data about the safety and efficacy of these devices has accumulated. The Resolute™ zotarolimus-eluting stent (R-ZES; Medtronic Inc., Santa Rosa, CA, USA) is a next-generation DES that uses a novel biocompatible polymer on a cobalt alloy stent platform to extend the duration of drug elution and improve the stent’s efficacy. The Integrity™ platform (Medtronic, Inc., Santa Rosa, CA, USA) used in the most recent iteration of the R-ZES stent further enhances the flexibility and deliverability of the stent in complex lesions by incorporation of a continuous sinusoidal design. In the following review, the clinical data is critically examined for the R-ZES and discuss its performance using comparative data currently available for next-generation DES. It is concluded that R-ZES use in complex patients and lesions is associated with durable efficacy and safety and represents another generational improvement in DES technology, which undoubtedly will enhance patient outcomes postpercutaneous coronary interventional.

Journal

Cardiology and Therapy – Springer Journals

Published: Jan 4, 2013

References

  • Meta-analysis comparing drug-eluting stents with bare metal stents
    Katritsis, DG; Karvouni, E; Ioannidis, JP
  • Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis
    Stettler, C; Wandel, S; Allemann, S
  • Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents
    Kastrati, A; Mehilli, J; Pache, J
  • Acute and 16-month outcomes of a new stent: the first-in-man evaluation of the Medtronic S9 (integrity) stent
    Lee, SW; Chan, MP; Chan, KK
  • Stent longitudinal integrity bench insights into a clinical problem
    Ormiston, JA; Webber, B; Webster, MW
  • Stent longitudinal flexibility: a comparison of 13 stent designs before and after balloon expansion
    Ormiston, JA; Dixon, SR; Webster, MW
  • Propensity and mechanisms of restenosis in different coronary stent designs: complementary value of the analysis of the luminal gain-loss relationship
    Escaned, J; Goicolea, J; Alfonso, F
  • Influence of stent design on 1-year outcome after coronary stent placement: a randomized comparison of five stent types in 1,147 unselected patients
    Kastrati, A; Dirschinger, J; Boekstegers, P
  • Restenosis after coronary placement of various stent types
    Kastrati, A; Mehilli, J; Dirschinger, J
  • Virtual bench testing of new generation coronary stents
    Mortier, P; Beule, M; Segers, P; Verdonck, P; Verhegghe, B
  • The next generation Endeavor Resolute Stent: role of the BioLinx Polymer System
    Udipi, K; Melder, RJ; Chen, M
  • Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial
    Meredith, IT; Worthley, S; Whitbourn, R
  • The next-generation Endeavor Resolute stent: 4-month clinical and angiographic results from the Endeavor Resolute first-in-man trial
    Meredith, IT; Worthley, S; Whitbourn, R
  • Rationale and design of the clinical evaluation of the Resolute Zotarolimus-Eluting Coronary Stent System in the treatment of de novo lesions in native coronary arteries (the RESOLUTE US clinical trial)
    Mauri, L; Leon, MB; Yeung, AC; Negoita, M; Keyes, MJ; Massaro, JM
  • Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial
    Yeung, AC; Leon, MB; Jain, A
  • Comparison of zotarolimus-eluting and everolimus-eluting coronary stents
    Serruys, PW; Silber, S; Garg, S
  • The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention)
    Stefanini, GG; Serruys, PW; Silber, S
  • Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial
    Silber, S; Windecker, S; Vranckx, P; Serruys, PW
  • Three-year outcomes from the randomized comparison of a Zotarolimus-eluting stent and an everolimus-eluting stent in the RESOLUTE All Comers Trial
    Silber, S; Windecker, S; Serruys, PW
  • One-year outcomes of patients with the zotarolimus-eluting coronary stent: RESOLUTE International Registry
    Neumann, FJ; Widimsky, P; Belardi, JA
  • The Resolute zotarolimus-eluting stent in patients with diabetes mellitus: two year outcomes
    Yeung, AC; Leon, M; Silber, S
  • Impact of sex on clinical and angiographic outcomes among patients undergoing revascularization with drug-eluting stents
    Stefanini, GG; Kalesan, B; Pilgrim, T
  • The twelve-month outcomes of a biolimus eluting stent with a biodegradable polymer compared with a sirolimus eluting stent with a durable polymer
    Garg, S; Sarno, G; Serruys, PW
  • Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial
    Kedhi, E; Joesoef, KS; McFadden, E
  • Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117,762 patient-years of follow-up from randomized trials
    Bangalore, S; Kumar, S; Fusaro, M
  • A randomized controlled trial in second-generation zotarolimus-eluting resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial
    Birgelen, C; Basalus, MWZ; Tandjung, K
  • Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial
    Byrne, RA; Kastrati, A; Kufner, S
  • Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial
    Massberg, S; Byrne, RA; Kastrati, A
  • Resolute Italian study in all comers: immediate and one-year outcomes
    Romagnoli, E; Godino, C; Ielasi, A
  • A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study)
    Krucoff, MW; Rutledge, DR; Gruberg, L
  • Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents/clinical perspective
    Räber, L; Wohlwend, L; Wigger, M
  • Long-term comparison of everolimus-eluting and sirolimus-eluting stents for coronary revascularization
    Raber, L; Juni, P; Nuesch, E
  • Thrombosis of second-generation drug-eluting stents in real practice results from the multicenter Spanish registry ESTROFA-2 (Estudio Espanol Sobre Trombosis de Stents Farmacoactivos de Segunda Generacion-2)
    Torre Hernandez, JM; Alfonso, F; Gimeno, F
  • Meta-analysis comparison (nine trials) of outcomes with drug-eluting stents versus bare metal stents in patients with diabetes mellitus
    Patti, G; Nusca, A; Sciascio, G
  • Differential clinical responses to everolimus-eluting and paclitaxel-eluting coronary stents in patients with and without diabetes mellitus
    Stone, GW; Kedhi, E; Kereiakes, DJ
  • Comparison of outcomes in patients with versus without diabetes mellitus after revascularization with everolimus- and sirolimus-eluting stents (from the SORT OUT IV Trial)
    Jensen, LO; Thayssen, P; Junker, A